AN2 Non Currrent Assets Other vs Deferred Long Term Liab Analysis

ANTX Stock

USD 2.10 0.11 5.53%

AN2 Therapeutics financial indicator trend analysis is way more than just evaluating AN2 Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AN2 Therapeutics is a good investment. Please check the relationship between AN2 Therapeutics Non Currrent Assets Other and its Deferred Long Term Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

Non Currrent Assets Other vs Deferred Long Term Liab

Non Currrent Assets Other vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AN2 Therapeutics Non Currrent Assets Other account and Deferred Long Term Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between AN2 Therapeutics' Non Currrent Assets Other and Deferred Long Term Liab is 0.64. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of AN2 Therapeutics, assuming nothing else is changed. The correlation between historical values of AN2 Therapeutics' Non Currrent Assets Other and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of AN2 Therapeutics are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Non Currrent Assets Other i.e., AN2 Therapeutics' Non Currrent Assets Other and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.64

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from AN2 Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AN2 Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.Selling General Administrative is likely to drop to about 7.7 M in 2024. Issuance Of Capital Stock is likely to drop to about 65.6 M in 2024

	2021	2022	2023	2024 (projected)
Interest Income	69K	1.4M	1.6M	1.6M
Net Interest Income	69K	1.4M	1.6M	1.6M

Interest Income Net Interest Income

AN2 Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Other Liab	Other Stockholder Equity	Net Invested Capital	Net Working Capital	Non Currrent Assets Other	Other Assets	Deferred Long Term Liab	Property Plant And Equipment Net	Non Current Liabilities Other	Short Term Debt
Total Assets		-0.79	0.86	0.88	0.75	0.78	-0.88	-0.92	0.93	0.87	0.99	0.81	0.19	0.94	0.33	1.0	-0.96	0.73	0.83	0.99	-0.85	-0.86	-0.56	-0.56	-0.56	-0.56
Short Long Term Debt Total	-0.79		-0.76	-0.77	-0.49	-0.55	0.75	0.8	-0.81	-0.7	-0.8	-0.59	-0.44	-0.82	-0.57	-0.8	0.85	-0.55	-0.64	-0.83	0.69	0.69	0.53	0.53	0.53	0.53
Other Current Liab	0.86	-0.76		1.0	0.88	0.89	-0.72	-0.99	0.97	0.67	0.84	0.94	-0.01	0.75	0.15	0.84	-0.82	0.94	0.94	0.86	-0.84	-0.98	-0.9	-0.9	-0.9	-0.9
Total Current Liabilities	0.88	-0.77	1.0		0.89	0.9	-0.76	-1.0	0.98	0.71	0.86	0.93	0.01	0.78	0.17	0.86	-0.85	0.93	0.94	0.89	-0.86	-0.98	-0.88	-0.88	-0.88	-0.88
Total Stockholder Equity	0.75	-0.49	0.88	0.89		1.0	-0.73	-0.87	0.87	0.7	0.74	0.85	-0.43	0.66	-0.27	0.74	-0.64	0.96	0.98	0.76	-0.91	-0.96	-0.79	-0.79	-0.79	-0.79
Net Tangible Assets	0.78	-0.55	0.89	0.9	1.0		-0.78	-0.89	0.89	0.75	0.78	0.84	-0.38	0.71	-0.22	0.78	-0.68	0.95	0.99	0.8	-0.94	-0.96	-0.77	-0.77	-0.77	-0.77
Net Debt	-0.88	0.75	-0.72	-0.76	-0.73	-0.78		0.8	-0.87	-0.99	-0.92	-0.55	-0.11	-0.97	-0.24	-0.92	0.89	-0.61	-0.8	-0.93	0.94	0.77	0.45	0.45	0.45	0.45
Retained Earnings	-0.92	0.8	-0.99	-1.0	-0.87	-0.89	0.8		-0.99	-0.75	-0.9	-0.92	-0.04	-0.83	-0.21	-0.9	0.88	-0.91	-0.94	-0.92	0.88	0.98	0.84	0.84	0.84	0.84
Accounts Payable	0.93	-0.81	0.97	0.98	0.87	0.89	-0.87	-0.99		0.83	0.93	0.86	0.08	0.89	0.24	0.93	-0.92	0.87	0.93	0.96	-0.92	-0.96	-0.79	-0.79	-0.79	-0.79
Cash	0.87	-0.7	0.67	0.71	0.7	0.75	-0.99	-0.75	0.83		0.91	0.51	0.1	0.96	0.22	0.91	-0.87	0.55	0.76	0.92	-0.92	-0.73	-0.37	-0.37	-0.37	-0.37
Cash And Short Term Investments	0.99	-0.8	0.84	0.86	0.74	0.78	-0.92	-0.9	0.93	0.91		0.76	0.21	0.97	0.35	1.0	-0.97	0.69	0.82	0.99	-0.87	-0.84	-0.53	-0.53	-0.53	-0.53
Common Stock Shares Outstanding	0.81	-0.59	0.94	0.93	0.85	0.84	-0.55	-0.92	0.86	0.51	0.76		-0.14	0.6	0.02	0.76	-0.7	0.94	0.87	0.76	-0.7	-0.93	-0.83	-0.83	-0.83	-0.83
Non Current Liabilities Total	0.19	-0.44	-0.01	0.01	-0.43	-0.38	-0.11	-0.04	0.08	0.1	0.21	-0.14		0.29	0.99	0.21	-0.4	-0.34	-0.28	0.22	0.17	0.17	0.13	0.13	0.13	0.13
Other Current Assets	0.94	-0.82	0.75	0.78	0.66	0.71	-0.97	-0.83	0.89	0.96	0.97	0.6	0.29		0.42	0.97	-0.96	0.57	0.75	0.97	-0.87	-0.76	-0.44	-0.44	-0.44	-0.44
Total Liab	0.33	-0.57	0.15	0.17	-0.27	-0.22	-0.24	-0.21	0.24	0.22	0.35	0.02	0.99	0.42		0.35	-0.54	-0.18	-0.12	0.37	0.02	0.0	-0.02	-0.02	-0.02	-0.02
Total Current Assets	1.0	-0.8	0.84	0.86	0.74	0.78	-0.92	-0.9	0.93	0.91	1.0	0.76	0.21	0.97	0.35		-0.97	0.69	0.82	0.99	-0.87	-0.84	-0.53	-0.53	-0.53	-0.53
Other Liab	-0.96	0.85	-0.82	-0.85	-0.64	-0.68	0.89	0.88	-0.92	-0.87	-0.97	-0.7	-0.4	-0.96	-0.54	-0.97		-0.62	-0.74	-0.98	0.8	0.79	0.56	0.56	0.56	0.56
Other Stockholder Equity	0.73	-0.55	0.94	0.93	0.96	0.95	-0.61	-0.91	0.87	0.55	0.69	0.94	-0.34	0.57	-0.18	0.69	-0.62		0.96	0.72	-0.81	-0.97	-0.9	-0.9	-0.9	-0.9
Net Invested Capital	0.83	-0.64	0.94	0.94	0.98	0.99	-0.8	-0.94	0.93	0.76	0.82	0.87	-0.28	0.75	-0.12	0.82	-0.74	0.96		0.84	-0.94	-0.98	-0.81	-0.81	-0.81	-0.81
Net Working Capital	0.99	-0.83	0.86	0.89	0.76	0.8	-0.93	-0.92	0.96	0.92	0.99	0.76	0.22	0.97	0.37	0.99	-0.98	0.72	0.84		-0.89	-0.87	-0.59	-0.59	-0.59	-0.59
Non Currrent Assets Other	-0.85	0.69	-0.84	-0.86	-0.91	-0.94	0.94	0.88	-0.92	-0.92	-0.87	-0.7	0.17	-0.87	0.02	-0.87	0.8	-0.81	-0.94	-0.89		0.9	0.64	0.64	0.64	0.64
Other Assets	-0.86	0.69	-0.98	-0.98	-0.96	-0.96	0.77	0.98	-0.96	-0.73	-0.84	-0.93	0.17	-0.76	0.0	-0.84	0.79	-0.97	-0.98	-0.87	0.9		0.86	0.86	0.86	0.86
Deferred Long Term Liab	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.44	-0.02	-0.53	0.56	-0.9	-0.81	-0.59	0.64	0.86		1.0	1.0	1.0
Property Plant And Equipment Net	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.44	-0.02	-0.53	0.56	-0.9	-0.81	-0.59	0.64	0.86	1.0		1.0	1.0
Non Current Liabilities Other	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.44	-0.02	-0.53	0.56	-0.9	-0.81	-0.59	0.64	0.86	1.0	1.0		1.0
Short Term Debt	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.44	-0.02	-0.53	0.56	-0.9	-0.81	-0.59	0.64	0.86	1.0	1.0	1.0

Click cells to compare fundamentals

AN2 Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GOOG	Alphabet Inc Class C
GM	General Motors
GM	General Motors

Additional Tools for AN2 Stock Analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AN2 Non Currrent Assets Other vs Deferred Long Term Liab Analysis

Non Currrent Assets Other vs Deferred Long Term Liab

Non Currrent Assets Other vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Non Currrent Assets Other

Deferred Long Term Liab

AN2 Therapeutics fundamental ratios Correlations

AN2 Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for AN2 Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Net	+ 1.0	Deferred Long Term Liab
Non Current Liabilities Other	+ 1.0	Deferred Long Term Liab

Retained Earnings	- 1.0	Total Current Liabilities
Accounts Payable	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Other Current Liab
Other Assets	- 0.98	Net Invested Capital
Net Working Capital	- 0.98	Other Liab